1513 results about "Anti cancer drugs" patented technology

This invention relates to compositions comprising thalidomide and another anti-cancer drug which can be used in the treatment or prevention of cancer. Preferred anti-cancer drugs are topoisomerase inhibitors. A particular composition comprises thalidomide, or a pharmaceutically acceptable salt, solvate, or clathrate thereof, and irinotecan. The invention also relates to methods of treating or preventing cancer which comprise the administration of a thalidomide and another anti-cancer drug to a patient in need of such treatment or prevention. The invention further relates to methods of reducing or avoiding adverse side effects associated with the administration of chemotherapy or radiation therapy which comprise the administration of thalidomide to a patient in need of such reduction or avoidance.

This invention relates to compositions comprising temozolomide and thalidomide which can be used in the treatment or prevention of cancer, in particular malignant melanoma, cancer of the skin, subcutaneous tissue, lymph nodes, brain, lung, liver, bone, intestine, colon, heart, pancreas, adrenals, kidney, prostate, breast, colorectal, or a combination thereof. A particular composition comprises temozolomide, or a pharmaceutically acceptable salt, solvate, or clathrate thereof, and thalidomide, or a pharmaceutically acceptable salt, solvate, or clathrate thereof. The invention also relates to methods of treating or preventing cancer, in particular malignant melanoma, cancer of the skin, subcutaneous tissue, lymph nodes, brain, lung, liver, bone, intestine, colon, heart, pancreas, adrenals, kidney, prostate, breast, colorectal, or a combination thereof, which comprise the administration of temozolomide and thalidomide and another anti-cancer drug to a patient in need of such treatment or prevention. The invention further relates to methods of reducing or avoiding adverse side effects associated with the administration of cancer chemotherapy or radiation therapy which comprise the administration of temozolomide and thalidomide to a patient in need of such reduction or avoidance.

The present invention provides a method for treating tumors or tumor metastases in a patient, comprising administering to the patient simultaneously or sequentially a therapeutically effective amount of an EGFR kinase inhibitor and gemcitabine combination, with or without additional agents or treatments, such as other anti-cancer drugs or radiation therapy. The invention also encompasses a pharmaceutical composition that is comprised of an EGFR kinase inhibitor and gemcitabine combination in combination with a pharmaceutically acceptable carrier. A preferred example of an EGFR kinase inhibitor that can be used in practicing this invention is the compound erlotinib HCl (also known as Tarceva™).

The present invention provides a method for treating NSCL, pancreatic, colon or breast cancer tumors or tumor metastases in a patient, comprising administering to the patient simultaneously or sequentially a therapeutically effective amount of a combination of an EGFR kinase inhibitor and an agent that sensitizes tumor cells to the effects of EGFR kinase inhibitors, wherein the agent is an mTOR inhibitor, with or without additional agents or treatments, such as other anti-cancer drugs or radiation therapy. The present invention also provides a method for treating tumors or tumor metastases in a patient, comprising administering to said patient simultaneously or sequentially a therapeutically effective amount of a combination of an EGFR kinase inhibitor and an agent that sensitizes tumor cells to the effects of EGFR kinase inhibitors, wherein said agent is an mTOR inhibitor that binds to and directly inhibits both mTORC1 and mTORC2 kinases. The present invention also provides a pharmaceutical composition comprising an EGFR kinase inhibitor and an mTOR inhibitor that binds to and directly inhibits both mTORC1 and mTORC2 kinases, in a pharmaceutically acceptable carrier. A preferred example of an EGFR kinase inhibitor that can be used in practicing the methods of this invention is the compound erlotinib HCl (also known as TARCEVA®).

The present invention provides a method for treating NSCL, pancreatic, colon or breast cancer tumors or tumor metastases in a patient, comprising administering to the patient simultaneously or sequentially a therapeutically effective amount of a combination of an EGFR kinase inhibitor and an agent that sensitizes tumor cells to the effects of EGFR kinase inhibitors, wherein the agent is an mTOR inhibitor, with or without additional agents or treatments, such as other anti-cancer drugs or radiation therapy. The present invention also provides a method for treating tumors or tumor metastases in a patient, comprising administering to said patient simultaneously or sequentially a therapeutically effective amount of a combination of an EGFR kinase inhibitor and an agent that sensitizes tumor cells to the effects of EGFR kinase inhibitors, wherein said agent is an mTOR inhibitor that binds to and directly inhibits both mTORC1 and mTORC2 kinases. The present invention also provides a pharmaceutical composition comprising an EGFR kinase inhibitor and an mTOR inhibitor that binds to and directly inhibits both mTORC1 and mTORC2 kinases, in a pharmaceutically acceptable carrier. A preferred example of an EGFR kinase inhibitor that can be used in practicing the methods of this invention is the compound erlotinib HCl (also known as TARCEVA®).

Compositions and methods are disclosed in embodiments relating to induction of cell death such as in cancer cells. Compounds and related methods for synthesis and use thereof, including the use of compounds in therapy for the treatment of cancer and selective induction of apoptosis in cells are disclosed. Compounds are disclosed that have lower neurotoxicity effects than other compounds.

The invention discloses a VEGF-resistant and PD-1-resistant difunctional antibody and application thereof, belonging to the technical field of molecular immunology. The VEGF-resistant and PD-1-resistant difunctional antibody contains a light chain an a heavy chain, wherein the light chain has an amino acid sequence as shown in SEQ ID NO.2, and the heavy chain has an amino acid sequence as shown in SEQ ID NO.4 or SEQ ID NO.6. Meanwhile, the invention provides a gene for encoding the difunctional antibody and the application of the difunctional antibody. The difunctional antibody provided by the invention can be combined with PD-1 and VEGF, has very high affinity, can be used for effectively simulating T cells to secrete IL2 and induce T cells to secrete IFN-gamma and can also be used for remarkably inhibiting the growth of tumor of a mouse so as to have a huge potential in application to preparation of anti-cancer drugs.

The invention relates to a copper sulfide / mesoporous silicon dioxide core-shell nano material as well as a preparation method and an application thereof. The chemical formula of the core-shell nano material is Cu9S5 / mSiO2-PEG. The preparation method comprises the following steps of: (1) raising the temperature of oleylamine under the protection of nitrogen; adding a mixed solution of copper dibutyldithiocarbamate and the oleylamine and dispersing the mixed solution into chloroform to prepare a D solution; (2) dissolving a surfactant into water; raising the temperature and adding the D solution to prepare an E solution; and (3) taking the E solution and adding ethanol; raising the temperature and adding an NaOH solution; immediately adding TEOS (Tetraethylorthosilicate) and reacting; adding PEG-silane; continually reacting and carrying out hydrothermal reaction; and adding into a scrubbing solution to centrifuge and wash to obtain the product. The copper sulfide / mesoporous silicon dioxide core-shell nano material is applied to near-infrared photo-thermal treatment, anti-cancer drugs, chemotherapy of tumors and infrared heat imaging. The nano material disclosed by the invention has very low cell toxicity and very high blood compatibility; and the united effects of thermal therapy and the chemotherapy are good.

The invention relates to small molecules which function as inhibitors of Stat3. The invention also relates to the use of these compounds for inducing cell death and sensitizing cells to the induction of cell death by anti-cancer drugs.

The present invention provides tumor cell preparations for use as models of the EMT process for use in the identification of anti-cancer agents, wherein said tumor cell preparations comprise cells of the epithelial tumor cell line H358, which are stimulated by receptor ligands to induce EMT, or which have been engineered to inducibly express a protein that stimulates EMT. The present invention also provides methods of identifying potential anti-cancer agents by using such tumor cell preparations to identify agents that inhibit EMT, stimulate MET, or inhibit the growth of mesenchymal-like cells. Such agents should be particularly useful when used in conjunction with other anti-cancer drugs such as EGFR and IGF-1R kinase inhibitors, which appear to be less effective at inhibiting tumor cells that have undergone an EMT.

A cell-targeted polymeric drug delivery system was designed based on the specific interaction between hyaluronic acid (HA) and its cell surface receptors overexpressed on cancer cell surface. The invention relates to compounds composed of a carrier molecule, 5 wherein the carrier molecule contains at least one residue of an anti-cancer agent and at least one residue of a hyaluronic acid. The invention also relates to methods of making and using the compounds thereof.

The invention provides a kit for detecting the epidermal growth factor receptor (EGFR) mutation by a primer specific fluorescence polymerase chain reaction (PCR), in particular to the diagnosis of the EGFR gene mutation in tumor tissues and peripheral blood serums of tumor patients. Aiming at specific mutant sites relative to the curative effects of molecular targeted anti-cancer drugs, the kit is provided with a specific oligonucleotide primer sequence and a probe sequence, carries out fluorescence PCR detection respectively through a wild type PCR system and a mutation type PCR system on each sample to be detected and judges whether the samples have the mutation of EGFR19 exons and 21 exons or not through the magnitude of a difference value (delta Ct) of Ct values of two times of reaction. The kit can detect whether the specific sites of the EDFR have the mutation or not and can be used for the curative effect forecast of new molecular targeted anti-cancer drugs and the guidance of clinical individualized medicine application programs of the tumor patients.

The invention relates to a nano micelle of a biodegradable macromolecular-bonding Pt(IV) anti-cancer medicament and a preparation method thereof. The structural formula of the anti-cancer medicament is defined in the specification, wherein the biodegradable macromolecule is tri-block copolymer, namely polyethylene glycol-b-polyester-b-polylysine; and tetravalency platinum coordination compound Pt(IV) is connected with a side amino on the block of polylysine on a macromolecular carrier through alpha, omega-polyethylene glycol. The carrier is non-toxic and is water-soluble, thus being convenient for reacting with the platinum(IV) coordination compound in water phase; a nano micelle form can be formed through self assembly; a platinum(IV) coordination compound is reduced to platinum(II), namely, cis-platinum, Carboplatin or Oxaliplatin, and the anti-cancer effect is known; the synthesis of the nano micelle is easy; the reduction potential of platinum(IV) is low, so that the platinum(IV) can be rapidly reduced to platinum(II) in cancer cells to take treatment effect; and the platinum(IV) is connected to the side chain of the macromolecule rather than the end of a chain, a macromolecular chain can be connected with multiple platinum(IV)s, and the content of platinum can be as high as 10-20%.

The invention discloses a pentadienone-containing 4-substituted quinazoline derivative. A structure of the pentadienone-containing 4-substituted quinazoline derivative is represented as the following general formula (I), wherein a group shown in the specification is at a position 2 or a position 3 or a position 4 of a benzene ring; R1 is hydrogen, monosubstituted halogen atom or polysubstituted halogen atom, monosubstituted methyl or polysubstituted methyl, or polysubstituted methoxy; R2 is ortho, meta, para monosubstituted or polysubstituted nitrophenyl, ortho, meta, para monosubstituted or polysubstituted halogen atom phenyl, ortho, meta, para monosubstituted or polysubstituted methoxyphenyl, 2-chlorine-5-nitrophenyl, 4-chlorine-3-nitrophenyl, ortho, meta, para monosubstituted trifluoromethylphenyl, five-membered heterocyclic aryl or substituted five-membered heterocyclic aryl, or ortho, meta, para monosubstituted or polysubstituted hydroxyphenyl. The invention further discloses a preparation method for the pentadienone-containing 4-substituted quinazoline derivative and a use of the pentadienone-containing 4-substituted quinazoline derivative in preparing anti-cancer drugs.

The invention relates to a slow-release injection of taxine anti-cancer drug, which comprises anti-cancer drug, slow-release finding, suspension and / or solvent. Wherein, said anti-cancer drug is taxine, 2'-hydroxy Paclitaxel, etc; the slow-release finding is polymer of hydroxyl, glycollic acid and glycolic acid, one of acetic acid ethyenyl ester polymer and polyphony; the suspension is polyphenyl (sodium), and mannite; the solvent is distilled water, injection water, absolute ethyl alcohol, etc. The invention can be injected to reduce the toxicity effect of drug, and improve the density locally to strengthen the treatment effect of chemotherapy and radiation therapy.

The present invention provides a method for treating tumors or tumor metastases in a patient, comprising administering to the patient simultaneously or sequentially a therapeutically effective amount of an EGFR kinase inhibitor and bortezomib combination, with or without additional agents or treatments, such as other anti-cancer drugs or radiation therapy. The invention also encompasses a pharmaceutical composition that is comprised of an EGFR kinase inhibitor and bortezomib combination in combination with a pharmaceutically acceptable carrier. A preferred example of an EGFR kinase inhibitor that can be used in practicing this invention is the compound erlitinib HCl (also known as Tarceva™).

The invention discloses a near-infrared fluorescent magnetic micro-emulsion nanometer particle, its preparation method and application in tumor treatment, wherein magnetic nano-particles and near-infrared luminescent quantum dot nano-particles or near-infrared luminescent organic dyestuff molecules are embedded into water-in-oil micro-emulsion, anti-cancer drugs can also be embedded into the micro-emulsion, the magnetic steering action of the magnetic nano particles will target the micro-emulsion embedded near-infrared fluorescent substances to tumor positions or secure them onto tumor positions under the excitation of near-infrared lights, the thermal effects produced by the near-infrared lights can kill tumor cells, the OH and O2 free radicals with high activity and the optical catalytic activity of the quantum dots can also have synergic actions in destroying tumor cells.

The present disclosure relates to methods and compositions to offset, ameliorate and / or alleviate one or more unwanted and / or adverse gastrointestinal effects. For example, in some embodiments, the present disclosure relates to compositions that include a bile acid, a carbohydrate and / or a pharmaceutical compound, wherein the pharmaceutical is associated with an adverse gastrointestinal effect in a subject (e.g., mammal or human). Non-limiting examples of pharmaceutical compounds may include a nonsteroidal anti-inflammatory drug, a gastric irritating drug (e.g., an antibiotic, an adrenal cortocoid steroid and an anti-cancer drug) and combinations thereof. The disclosure further relates to methods of ameliorating or eliminating at least one adverse gastrointestinal effects of a composition, comprising administering to a subject an aqueous solution comprising a bile acid and a carbohydrate.

The present invention provides a method for treating tumors or tumor metastases in a patient, comprising administering to the patient simultaneously or sequentially a therapeutically effective amount of an EGFR kinase inhibitor and cisplatin combination, with or without additional agents or treatments, such as other anti-cancer drugs or radiation therapy. The invention also encompasses a pharmaceutical composition that is comprised of an EGFR kinase inhibitor and cisplatin combination in combination with a pharmaceutically acceptable carrier. A preferred example of an EGFR kinase inhibitor that can be used in practicing this invention is the compound erlotinib HCl (also known as Tarceva™).

The present invention is based, in part, on the identification of novel methods for defining predictive biomarkers of response to anti-cancer drugs.

Disclosed is an anti solid tumor medicine composition, which comprises medicinal adjuvant and DNA restoring enzyme inhibitor and / or Nitrosoureas anti-cancer drugs, wherein the DAN restoring enzyme inhibitor is selected from methoxamine, hydroxylamine and their analogues, which can effectively destroy the DNA restoring function in the tumor cells, and lower the survivability of tumor cell to Semustine anti-cancer drugs and their analogues, the medicinal adjuvant is biological compactable, degradable and absorbing macromolecular polymer, which can slowly release the DNA restoring enzyme inhibitor onto tumor partially during the degradation and absorption process, thus the whole body toxicity reaction is reduced appreciably , and the effective medicinal concentration can be sustained to the tumor partially. By dispensing the composition to the tumor partially, the whole body toxicity reaction of Nitrosoureas anti-cancer drugs and / or DNA restoring enzyme inhibitor can be lowered, selectively increase the tumor local medicinal concentration, and the treatment effect of the non-operative treatment methods such as chemotherapy, medicament and radiation can be improved.

The invention discloses a cancer driving gene screening method based on gene mutation frequency and belongs to the field of cancer medicine. The method comprises the steps that (1) tumor gene mutation data is acquired; (2) the mutation data is preprocessed; (3) adjacent genes of each gene are screened; (4) background mutation data of each kind of mutation is calculated; and (5) hypothesis testing is used to screen mutation genes according to mutation values. According to the method, a modern high-throughput sequencing technology, DNA data processing software, a classic clustering algorithm and a classic statistical method are utilized and combined with biotic factors influencing gene mutation, so that screening of cancer driving genes is more precise, and the method has an important meaning for both research and development of novel anti-cancer drugs and clinical diagnosis and treatment of cancers.

The invention provides a preparation method of a supramolecular anti-cancer drug (dicycloplatin). The preparation method comprises the following steps of: adding carboplatin and 1,1-cyclobutanedicarboxylic acid into water according to the mol ratio of 1:1, dissolving and uniformly mixing to obtain the mixed solution, and standing the mixed solution in a dark place at the temperature of more than 0 DEG C and less than or equal to 60 DEG C for 3-9 days, and concentrating under reduced pressure or freeze-drying so as to obtain dicycloplatin. The preparation method disclosed by the invention is moderate in condition and environment friendly; both the yield and the purity of dicycloplatin can be up to nearly 100%; the batch yield can reach 1000g; and thus, the preparation method is particularly applied to industrial production.

The invention discloses a nano-drug carrier with the magnetothermal and photothermal effects. The particle size is 50 nanometers to 300 nanometers, and the nano-drug carrier is prepared from mesoporous silica particles, Fe3O4 nanoparticles embedded into the mesoporous silica particles and graphene oxide with which the surfaces of the mesoporous silica particles are coated. The invention further provides a preparation method of the nano-drug carrier. The superparamagnetic Fe3O4 nanoparticles are prepared through a solvothermal method, the Fe3O4 nanoparticles are composited by taking hexadecyl trimethyl ammonium bromide as a structure-directing agent and taking tetraethoxysilane as a silicon source through the sol-gel self-assembling process, and then magnetic mesoporous nanoparticles Fe3O4 / mSiO2 with the magnetic property adjustable and controllable are prepared; the surfaces of the Fe3O4 / mSiO2 mesoporous nanoparticles are coated with graphene through the ion interaction or electrostatic interaction or hydrogen-bond interaction, and then the nano-drug carrier which both can efficiently deliver anti-cancer drugs and has the magnetothermal and photothermal effects is obtained. Accordingly, cancer treatment in which medical chemotherapy cooperates with magnetothermal and photothermal treatment can be achieved.

The invention discloses a method of catalyzing and synthesizing alpha-glyceryl linolenate with immobilized lipolytic enzyme in the manufacturing method field of a anti-cancer drug material, which comprises the following steps: making immobilized enzyme carrier including hole enlarge of dielectric hole material and the amido modification; making immobilized lipolytic enzyme, synthesizing alpha-glyceryl linolenate with immobilized enzyme in organic medium. The invention provides a good steady, and SBA-15 still shows regular hexagonal structure after modification, a uniform pore path, a big aperture and meets the need of synthesizing alpha-glyceryl linolenate; improvement of the lipase proper temperature improves the productivity; the product is provided with a light yellow color, a good quality, a good curative effect, enhancing heat stability.

The present invention provides a method for treating tumors or tumor metastases in a patient, comprising administering to the patient simultaneously or sequentially a therapeutically effective amount of an EGFR kinase inhibitor and capecitabine combination, with or without additional agents or treatments, such as other anti-cancer drugs or radiation therapy. The invention also encompasses a pharmaceutical composition that is comprised of an EGFR kinase inhibitor and capecitabine combination in combination with a pharmaceutically acceptable carrier. A preferred example of an EGFR kinase inhibitor that can be used in practicing this invention is the compound erlotinib HCl (also known as TARCEVA®).

Methods for treating and preventing the onset and maintainance of multiple drug resistance (MDR) in animals undergoing chemotherapy for cancer are provided. According to the methods, target cells are depleted of adenosine 5'-monophosphate (AMP) and adenosine 5'-triphosphate (ATP) such that the cells are unable to support P-glycoprotein activity. According to one method, a population of target cells is obtained from a host and assayed for loss of methylthioadenosine phosphorylase (MTAse) activity. MTAse catabolizes methylthioadenosine to adenine for endogenous salvage incorporation into the intracellular AMP pool. MTAse deficient cells are treated with a purine synthesis inhibitor, such as L-alanosine, which starves the cells of adenine and suppresses P-glycoprotein activity. MTAse competent cells are also treated for MDR with purine synthesis inhibitors. In conjunction with treatment according to the invention, MTAse competent and deficient cells are also treated for malignancy with other anti-cancer drugs. A method for protecting non-malignant cells from adenine starvation during treatment of malignant cells according to the invention is provided.

The invention belongs to the field of synthesis of drug carrier base materials and provides a nano particle-polymer injectable composite hydrogel double drug loading system and a preparation method thereof. The double drug loading system is loaded with not only an anti-cancer drug I of which polymer nano particles are synthesized through a disulfide bond cross-linking agent by taking acrylic acidand 4-vinylphenylboric acid as monomers, but also an anti-cancer drug II of which injectable hydrogel is synthesized through Michael addition reaction between a macromolecular cross-linking agent witha sulfhydryl functional group and a polymer containing a catechol functional group aiming at the drug loading capacity, the action time, the treatment effect and other demands. The bi-stimulus response is pH stimulus response and reducing stimulus response of glutathione to the disulfide bond cross-linking agent in a tumor cell environment respectively, the interaction between the nano particlesand the drug I as well as the degradation process of the nano particle can be affected, and the long-term delivery of the drug I is realized. The nano particle-polymer injectable composite hydrogel double drug loading system provided by the invention realizes the effects of local long-time administration, step-by-step osmotic treatment and combined treatment of a variety of drugs.

This invention features methods of identifying genetic alterations that can modulate cancer cells' sensitivity to an anti-cancer drug. Information on such genetic alterations can be used to predict cancer therapeutic outcomes and to stratify patient populations to maximize therapeutic efficacy.

The present invention relates to integrin ligand modified long circulation liposome carrying anticarcinogen for injection, and is especially one kind of injected anticarcinogen carrying targeting liposome administration system. The efficient administration system is obtained through modifying the surface of liposome simultaneously with both polyethylene glycol and integrin containing arginine-glycine-asparagic acid sequence or RGD analogue.